Ying Shi

Dr. Ying Shi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
FMFang Miao
Fang Miao
MSMeng-Yun Su
Meng-Yun Su
SJShan Jiang
Shan Jiang
LLLong-Fei Luo
Long-Fei Luo
YSYing Shi
Ying Shi
TLTie-Chi Lei
Tie-Chi Lei
Although vitamin C (VC, L-ascorbic acid) has been widely used as a skin lightening agent for a long time, the mechanism by which it inhibits melanogenesis remains poorly understood. It is well-documented that the intramelanocytic pH is an important factor in regulating tyrosinase function and melanosome maturation. The activity of tyrosinase, the rate-limiting enzyme required for melanin synthesis, is generally minimal in an acidic environment. Given that VC is an acidic compound, we might speculate that the intracellular acidification of melanocytes induced by VC likely reduces melanin content through the suppression of tyrosinase activity. The results of this study reveal that treatment of melanocytes with VC or its derivatives, magnesium ascorbyl phosphate (MAP) and 3-O-ethyl-L-ascorbic acid (AAE), resulted in significant decreases in the tyrosinase activity and melanin content and in the levels of intracellular reactive oxygen species (ROS), indicating that VC and its derivatives possess antimelanogenic and antioxidative activities. Western blotting analysis indicated that VC, MAP, and AAE exert their antimelanogenic activity by inhibiting the tyrosinase activity rather than by downregulating the expression of melanogenic proteins such as tyrosinase, premelanosome protein 17 (Pmel17) and microphthalmia-associated transcription factor (MITF). Further, we found that the reduced tyrosinase activity of melanocytes treated with VC or its derivatives could be reactivated following intracellular neutralization induced by ammonium chloride (NH4Cl) or concanamycin A (Con A). Finally, we examined the expression of sodium-dependent VC transporter-2 (SVCT-2) using western blotting and qPCR, which revealed that there was a significant increase in the expression of SVCT-2 in melanocytes following treatment with VC. VC-mediated intracellular acidification was neutralized by phloretin (a putative SVCT-2 inhibitor) in a dose-dependent manner. Taken together, these data show that VC and its derivatives suppress tyrosinase activity through cytoplasmic acidification that potentially results from enhanced VC transmembrane transport via the VC transporter SVCT-2.

1 November 2019 in Experimental Cell Research
Verified
Journal Article
Closed access
MSMengyun Su
Mengyun Su
HYHong Yi
Hong Yi
XHXiaolei He
Xiaolei He
LLLongfei Luo
Longfei Luo
SJShan Jiang
Shan Jiang
YSYing Shi
Ying Shi

13 October 2025 in Biology
Verified
Journal Article
Open access
PDF file
FMFang Miao
Fang Miao
JWJing Wan
Jing Wan
YZYouwen Zhou
Youwen Zhou
YSYing Shi
Ying Shi
Melasma is a chronic, acquired hyperpigmentation disease that occurs on light-exposed skin, especially in women of childbearing age. This common dyschromic disorder significantly impairs quality of life, yet treatments are unsatisfactory due to an incomplete understanding of its etiology. Its pathogenesis is multifactorial: ultraviolet (UV) radiation exposure, sex hormone fluctuations, and familial genetics are known triggers. Meanwhile, the persistence of focal hyperpigmentation suggests additional mechanisms beyond enhanced melanocyte activity. Emerging evidence highlights that melasma skin exhibits features of chronic photoaging: solar elastosis, basement membrane (BM) disruption and increased vascularity can be seen in the skin lesions. Senescent dermal fibroblasts under UV stress secrete melanogenic cytokines (e.g., SCF, HGF) that further stimulate melanocytes. In addition, melasma lesions harbor subclinical inflammation: infiltrates of CD4+ T cells, macrophages, and mast cells are visible, accompanied by elevated IL-17 and COX-2, implying an immune-driven component sustains pigment production. Collectively, these observations suggest that melasma behaves as a chronic inflammatory disorder of the skin microenvironment, rather than an isolated pigmentary defect. Concurrently, epidermal alterations such as barrier dysfunction and abnormal melanosome transport exacerbate melanin retention. In this review, by integrating these emerging insights into a unified pathogenic framework, we recognize melasma as a disorder of epidermal–dermal crosstalk and immune modulation, offering novel therapeutic perspectives for this recalcitrant condition.

14 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LLLongfei Luo
Longfei Luo
XHXiaolei He
Xiaolei He
YSYing Shi
Ying Shi
Background: Vitiligo is a chronic autoimmune disorder characterized by CD8+ T cell-mediated destruction of melanocytes. It affects up to 2% of the global population and has a profound psychosocial impact. Over the past two decades, advances in understanding immunological mechanisms, particularly IFN-γ signaling and JAK-STAT pathway dysregulation, have reshaped therapeutic approaches from empirical regimens to targeted immunomodulatory interventions. Objective: To analyze global vitiligo treatment research trends from 2005 to 2025, examining publication patterns, collaboration networks, and the evolution of therapeutic strategies. Methods: Publications related to vitiligo treatment were retrieved from the Web of Science Core Collection (WoSCC) and analyzed using R (Bibliometrix), VOSviewer, and CiteSpace. Scopus database was used for supplementary validation of major trends. In parallel, randomized controlled trials (RCTs) were systematically identified from PubMed to contextualize clinical research. Results: In total, 3, 483 publications were included in this study. Annual output increased at a compound growth rate of 7.27%. China, the United States, and India were the leading contributors, whereas the Egyptian Knowledge Bank and Harvard University were the most productive institutions. Thematic analysis revealed a gradual transition from traditional therapies such as corticosteroids and phototherapy to immune-targeted strategies. Citation bursts highlight the emergence of JAK inhibitors and biologics. Network analyses revealed fragmented author clusters, but strong international collaborations, particularly in Europe. An analysis of 249 RCTs revealed that pharmacological therapies, surgical interventions, and phototherapy constitute the three major research themes. Immunomodulatory therapies, particularly JAK inhibitors, such as ritlecitinib, have emerged as a key focus in ongoing clinical trials. Conclusion: This multi-database analysis delineates the evolving landscape of vitiligo treatment research, characterized by expanding output and increasing focus on immune-targeted therapies. Persistent gaps in clinical evidence, especially regarding long-term outcomes and pediatric populations, underscore the need for continued high-quality clinical studies in this field.

Verified
Journal Article
Open access
PDF file
FMFang Miao
Fang Miao
XLXiaohui Li
Xiaohui Li
LZLiang Zhao
Liang Zhao
SZShijiao Zhang
Shijiao Zhang
MGMengmeng Geng
Mengmeng Geng
TLTie-Chi Lei
Tie-Chi Lei
Autoimmune CD8+ T cell-driven melanocyte destruction constitutes a key pathogenic mechanism in the development of vitiligo. Therefore, the pharmacological inhibition of CD8+ T cell effector functions and skin trafficking is a clinically viable therapeutic strategy. This study investigates leflunomide (LEF), an immunomodulatory drug with established safety in autoimmune diseases, for its therapeutic potential in a tyrosine-related protein (TRP) 2-180-induced vitiligo mouse model. Through flow cytometry, immunofluorescence, ELISA, and histopathological analyses, we systematically evaluated LEF’s effects on T cell regulation, chemokine expression, and cytokine profiles. Key findings demonstrated that LEF (20 mg/kg/day) significantly attenuated depigmentation by reducing CD8+ T cell infiltration and suppressing the IFN-γ-driven expression of CXCL9/10. Furthermore, LEF restored CD4+/CD8+ T cell homeostasis and rebalanced pro-inflammatory (IFN-γ, TNF-α, IL-2) and anti-inflammatory (IL-4, IL-10) cytokines, inducing a shift from Th1 to Th2. These results position LEF as an effective immunomodulator that disrupts the IFN-γ-CXCL9/10 axis and re-establishes immune balance, offering a promising repurposing strategy for halting vitiligo progression.

12 March 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YCYan Chen
Yan Chen
YSYing Shi
Ying Shi
Bednar tumors are rare pigmented variants of dermatofibrosarcoma protuberans (DFSP), accounting for less than 5% of DFSP cases. We report a rare case of a congenitally pigmented lesion that progressively enlarged during pregnancy and developed pain. A 32-year-old woman presented with a blue-black nodule on her right shoulder, which had been present since birth and was initially misdiagnosed as a blue nevus. Histopathological analysis revealed spindle cell proliferation in a storiform pattern with focal melanin pigment. Immunohistochemistry showed strong CD34 positivity and negative S100 staining, consistent with Bednar tumors. This case highlights the importance of considering Bednar tumors in the differential diagnosis of congenital pigmented lesions, particularly those showing interval growth or symptoms.